Shamburg News · 8-K filed Oct 23, 2026, 4:15 PM EDT
AEON Biopharma Furnishes October 2026 Corporate Presentation Under Regulation FD
AEON · AEON Biopharma, Inc.
- Reg FD disclosure
- Other event
- Materiality: low
On October 23, 2026, AEON Biopharma, Inc. made available in the investor relations section of its website a corporate presentation dated October 2026, furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The presentation covers the company's development of ABP-450 as a potential biosimilar to BOTOX, its FDA interactions, and its planned IND submission for a CMAP pharmacodynamic study in Q4 2026. The information is furnished and not deemed filed under Section 18 of the Exchange Act.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001837607-26-000071.
Written from the filing by Shamburg Markets. Figures are as reported by the company.